Jump to content

Sabcomeline

From Wikipedia, the free encyclopedia
Sabcomeline
Clinical data
ATC code
  • None
Legal status
Legal status
  • Never marketed
Identifiers
  • (3Z,3R)-N-methoxy-1-azabicyclo[2.2.2]octane-3-carboximidoyl cyanide
CAS Number
PubChemCID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC10H15N3O
Molar mass193.250g·mol−1
3D model (JSmol)
  • C2CC1CCN2CC1\C(\C#N)=N\OC

Sabcomeline(Memric;SB-202,026) is aselectiveM1receptorpartial agonistthat was under development for the treatment ofAlzheimer's disease.[1]It made it tophase IIIclinical trialsbefore being discontinued due to poor results.

See also

[edit]

References

[edit]
  1. ^Loudon JM, Bromidge SM, Brown F, et al. (December 1997)."SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors".The Journal of Pharmacology and Experimental Therapeutics.283(3): 1059–68.PMID9399977.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Sabcomeline&oldid=1217260248"